Michael S Gordon

7PUBLICATIONS
78CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Pharmaceutical delivery technologies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 28, 2026
Extended Follow-Up of Botensilimab Plus Balstilimab in an Expanded Cohort of Microsatellite-Stable Metastatic Colorectal Cancer Without Active Liver Metastases.

|Mar 05, 2026
BET inhibitor OPN-2853 in advanced solid tumors and lymphoma: results from the phase 1b PLX124-01 trial.

Michael S Gordon, Richard D Carvajal, Alexander Spira

|Jan 27, 2026
Correlative Biomarker Analysis of PSMA Expression on CTCs and PSMA Imaging in a Phase I Study of PSMA-Targeted Tubulysin Conjugate EC1169.

Samir Zaidi, Phillip H Kuo, Tiago Paiva Prudente

|Jan 27, 2025
Botensilimab (Fc-enhanced anti-cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti-PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas.

Breelyn A Wilky, Gary K Schwartz, Michael S Gordon

|Jun 14, 2022
First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors.

Tae Won Kim, Howard A Burris, Maria J de Miguel Luken

|Jul 28, 2021
Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors.

Michael S Gordon, John Nemunaitis, Minal Barve

Pageof 2

Frequent Collaborators

2 joint publications

Manushak Avagyan

2 joint publications

Joseph E Grossman

2 joint publications

Dhan Chand

2 joint publications

Apostolia M Tsimberidou